{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:17:17Z","timestamp":1783606637082,"version":"3.55.0"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"11","funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior - Brasil","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2020,9,21]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Vancomycin is the first-line antibiotic used for the treatment of staphylococcal\ninfections. Because of its narrow therapeutic window and the pharmacokinetics variability, vancomycin\ntrough serum concentration should be monitored. However, due to the increased cases of staphylococcus\u2019\ncommensal species infections and the case of vancomycin resistance, the minimal inhibitory\nconcentration should be considered on antimicrobial therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This article aimed to show the importance of the minimal inhibitory concentration to infants\non vancomycin therapy as regular criteria.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>Three infants in the use of vancomycin, hospitalized in the same maternity\nhospital, and that had at least one blood culture performed during the intensive-care-unit hospitalization\nwere included in the study. Vancomycin serum concentrations were determined by particleenhanced-\nturbidimetric inhibition-immunoassay. The vancomycin minimal inhibitory concentration\ndata were interpreted by following the Clinical and Laboratory Standards Institute (CLSI) and the European\nCommittee on Antimicrobial Susceptibility Testing (EUCAST). The trough serum concentration\nrange of 10 to 20 mg.L-1 was considered therapeutic.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>All three patients had at least one infection by S. epidermidis, being one patient exhibit vancomycin-\nresistant S. epidermidis infection. All patients had stoppages in the vancomycin treatment,\nand the minimal inhibitory concentration was performed for only one patient.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The data obtained from these patients also showed the need to perform therapeutic monitoring\nby using minimal inhibitory concentration values, because, although the serum concentrations\nwere within the reference range, they are insufficient to guarantee patient therapeutic success.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201021666200327162402","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T16:22:23Z","timestamp":1585326143000},"page":"1052-1058","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Should the Vancomycin Minimal Inhibitory Concentration be used as an Infant Critical Care Regular Criteria?"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-1044","authenticated-orcid":true,"given":"Nadielle S.","family":"Bidu","sequence":"first","affiliation":[{"name":"Pharmacy Postgraduate Program, Faculty of Pharmacy, Federal University of Bahia\/UFBA, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno J.D.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia\/UFBA, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jucelino N.C.","family":"Filho","sequence":"additional","affiliation":[{"name":"Pharmacy Postgraduate Program, Faculty of Pharmacy, Federal University of Bahia\/UFBA, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina E.A.","family":"Bastos","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Roberto Santos, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joice N.R.","family":"Pedreira","sequence":"additional","affiliation":[{"name":"Pharmacy Postgraduate Program, Faculty of Pharmacy, Federal University of Bahia\/UFBA, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo D.","family":"Couto","sequence":"additional","affiliation":[{"name":"Pharmacy Postgraduate Program, Faculty of Pharmacy, Federal University of Bahia\/UFBA, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"62","volume":"82","author":"da Silva A.C.S.S.","year":"2017","unstructured":"da Silva A.C.S.S.; dos Santos \u00c9.I.; Penha R.S.; Dutra L.B.; Barreiros R.N.; Ribeiro I.V.; Evid\u00eancias cient\u00edficas brasileiras acerca da infec\u00e7\u00e3o prim\u00e1ria da corrente sangu\u00ednea em pediatria. Rev Enferm Atual 2017,82,62-70","journal-title":"Rev Enferm Atual"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMra0904124","volume":"362","author":"Peleg A.Y.","year":"2010","unstructured":"Peleg A.Y.; Hooper D.C.; Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010,362(19),1804-1813","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/0972-5229.148633","volume":"19","author":"Dasgupta S.","year":"2015","unstructured":"Dasgupta S.; Das S.; Chawan N.S.; Hazra A.; Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med 2015,19(1),14-20","journal-title":"Indian J Crit Care Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1128\/AAC.00726-16","volume":"60","author":"Chong J.","year":"2016","unstructured":"Chong J.; Quach C.; Blanchard A.C.; Poliquin P.G.; Golding G.R.; Laferri\u00e8re C.; L\u00e9vesque S.; Molecular epidemiology of a vancomycin-intermediate heteroresistant Staphylococcus epidermidis outbreak in a neonatal intensive care unit. Antimicrob Agents Chemother 2016,60(10),5673-5681","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2013.e3","volume":"5","author":"Wang N.","year":"2013","unstructured":"Wang N.; Neilan A.M.; Klompas M.; Staphylococcus intermedius infections: Case report and literature review. Infect Dis Rep 2013,5(1)","journal-title":"Infect Dis Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/apm.12591","volume":"124","author":"Cavanagh J.P.","year":"2016","unstructured":"Cavanagh J.P.; Wolden R.; Heise P.; Esaiassen E.; Klingenberg C.; Aarag F.E.G.; Antimicrobial susceptibility and body site distribution of community isolates of coagulase-negative staphylococci. APMIS 2016,124(11),973-978","journal-title":"APMIS"},{"key":"ref=7","first-page":"261","volume":"69","author":"Ahmed A.","year":"2019","unstructured":"Ahmed A.; Satti L.; Zaman G.; Gardezi A.; Sabir N.; Khadim M.T.; Catheter related recurrent blood stream infection caused by linezolid-resistant, methicillin resistant Staphylococcus haemolyticus; An emerging super bug. J Pak Med Assoc 2019,69(2),261-263","journal-title":"J Pak Med Assoc"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12941-017-0238-5","volume":"16","author":"Mashaly G.E.S.","year":"2017","unstructured":"Mashaly G.E.S.; El-Mahdy R.H.; Vancomycin heteroresistance in coagulase negative Staphylococcus blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt. Ann Clin Microbiol Antimicrob 2017,16(1),63","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1471-2431-14-193","volume":"14","author":"Sinkeler F.S.","year":"2014","unstructured":"Sinkeler F.S.; de Haan T.R.; Hodiamont C.J.; Bijleveld Y.A.; Pajkrt D.; Math\u00f4t R.A.A.; Inadequate vancomycin therapy in term and preterm neonates: A retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr 2014,14(1),193","journal-title":"BMC Pediatr"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1590\/0074-0276130644","volume":"108","author":"Pereira V.C.","year":"2013","unstructured":"Pereira V.C.; Cunha, Mde. L. Coagulase-negative staphylococci strains resistant to oxacillin isolated from neonatal blood cultures. Mem Inst Oswaldo Cruz 2013,108(7),939-942","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164136","volume":"11","author":"Chong J.","year":"2016","unstructured":"Chong J.; Caya C.; L\u00e9vesque S.; Quach C.; Heteroresistant vancomycin intermediate coagulase negative staphylococcus in the NICU: A systematic review. PLoS One 2016,11(10)","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2169\/internalmedicine.56.7715","volume":"56","author":"Yamada K.","year":"2017","unstructured":"Yamada K.; Namikawa H.; Fujimoto H.; Nakaie K.; Takizawa E.; Okada Y.; Fujita A.; Kawaguchi H.; Nakamura Y.; Abe J.; Kaneko Y.; Kakeya H.; clinical characteristics of methicillin-resistant coagulase-negative staphylococcal bacteremia in a tertiary hospital. Intern Med 2017,56(7),781-785","journal-title":"Intern Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"van Hal S.J.","year":"2012","unstructured":"van Hal S.J.; Lodise T.P.; Paterson D.L.; The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012,54(6),755-771","journal-title":"Clin Infect Dis"},{"key":"ref=14","first-page":"1521","author":"Macdougall C.","year":"2012","unstructured":"Macdougall C.; Chambers H.F.;  2012,1521-1547"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/CMR.15.3.430-438.2002","volume":"15","author":"Srinivasan A.","year":"2002","unstructured":"Srinivasan A.; Dick J.D.; Perl T.M.; Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002,15(3),430-438","journal-title":"Clin Microbiol Rev"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/781679","volume":"2012","author":"Sujatha S.","year":"2012","unstructured":"Sujatha S.; Praharaj I.; Glycopeptide resistance in gram-positive cocci: A review. Interdiscip Perspect Infect Dis 2012,2012","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"ref=17","first-page":"S3","volume":"42","author":"Moellering R.C.","year":"2006","unstructured":"Moellering R.C.; Jr, Vancomycin: A 50-year reassessment. Clin. Infect. Dis. 2006,42(Supplement_1),S3-4"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"Rybak M.J.","year":"2009","unstructured":"Rybak M.J.; Lomaestro B.M.; Rotschafer J.C.; Moellering R.C.; Craig W.A.; Billeter M.; Dalovisio J.R.; Levine D.P.; Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009,49(3),325-327","journal-title":"Clin Infect Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0034-1398490","volume":"36","author":"Abdul-Aziz M.H.","year":"2015","unstructured":"Abdul-Aziz M.H.; Lipman J.; Mouton J.W.; Hope W.W.; Roberts J.A.; Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: Optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015,36(1),136-153","journal-title":"Semin Respir Crit Care Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bjid.2012.06.011","volume":"16","author":"Silva D.C.B.","year":"2012","unstructured":"Silva D.C.B.; Seixas G.T.F.; Ara\u00fajo O.R.; Arduini R.G.; Carlesse F.A.; Petrilli A.S.; Vancomycin serum concentrations in pediatric oncologic\/hematologic intensive care patients. Braz J Infect Dis 2012,16(4),361-365","journal-title":"Braz J Infect Dis"},{"key":"ref=21","first-page":"321","volume":"8","author":"Santos A.B.","year":"2011","unstructured":"Santos A.B.; Duarte A.; Sai\u00e3o A.S.; Vancomycin in clinical practice - a review. JBBR 2011,8(2),321-327","journal-title":"JBBR"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ackd.2010.05.007","volume":"17","author":"Eyler R.F.","year":"2010","unstructured":"Eyler R.F.; Mueller B.A.; Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv Chronic Kidney Dis 2010,17(5),392-403","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/08998280.2001.11927763","volume":"14","author":"James C.W.","year":"2001","unstructured":"James C.W.; Gurk-Turner C.; Recommendations for monitoring serum vancomycin concentrations. Proc Bayl Univ Med Cent 2001,14(2),189-190","journal-title":"Proc Bayl Univ Med Cent"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","volume":"48","author":"Andrews J.M.","year":"2001","unstructured":"Andrews J.M.; Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001,48(Suppl. 1),5-16","journal-title":"J Antimicrob Chemother"},{"key":"ref=25","first-page":"86","volume":"14","author":"Benner K.W.","year":"2009","unstructured":"Benner K.W.; Worthington M.A.; Kimberlin D.W.; Hill K.; Buckley K.; Tofil N.M.; Correlation of vancomycin dosing to serum concentrations in pediatric patients: A retrospective database review. J Pediatr Pharmacol Ther 2009,14(2),86-93","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref=26","first-page":"423","volume":"38","author":"Navarini A.","year":"2015","unstructured":"Navarini A.; Martino M.D.V.; Sasagawa S.M.; Massaia I.F.D.; Mimica M.J.; Accuracy of a vancomycin brain heart infusion screening plate for the screening of Staphylococcus aureus isolates with increased vancomycin minimum inhibitory concentrations. New Microbiol 2015,38(3),423-426","journal-title":"New Microbiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","volume":"34","author":"Yamamoto M.","year":"2009","unstructured":"Yamamoto M.; Kuzuya T.; Baba H.; Yamada K.; Nabeshima T.; Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther 2009,34(4),473-483","journal-title":"J Clin Pharm Ther"},{"key":"ref=28","first-page":"393","author":"Ambrose P.J.","year":"2012","unstructured":"Ambrose P.J.; Winter M.; Farmacocin\u00e9tica Cl\u00ednica B\u00e1sica, Winter, 4\u00aa Ed.; S\u00e3o Paulo, 2012,393-409"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.6061\/clinics\/2012(07)21","volume":"67","author":"Pacifici G.M.","year":"2012","unstructured":"Pacifici G.M.; Allegaert K.; Clinical pharmacokinetics of vancomycin in the neonate. A review. Clinics (S\u00e3o Paulo) 2012,67(7),831-837"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1365-2125.2010.03736.x","volume":"70","author":"Marqu\u00e9s-Mi\u00f1ana M.R.","year":"2010","unstructured":"Marqu\u00e9s-Mi\u00f1ana M.R.; Saadeddin A.; Peris J.E.; Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol 2010,70(5),713-720","journal-title":"Br J Clin Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099044","volume":"9","author":"Ye Z.K.","year":"2014","unstructured":"Ye Z.K.; Li C.; Zhai S.D.; Guidelines for therapeutic drug monitoring of vancomycin: A systematic review. PLoS One 2014,9(6)","journal-title":"PLoS One"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/imj.12036","volume":"43","author":"Avent M.L.","year":"2013","unstructured":"Avent M.L.; Vaska V.L.; Rogers B.A.; Cheng A.C.; van Hal S.J.; Holmes N.E.; Howden B.P.; Paterson D.L.; Vancomycin therapeutics and monitoring: A contemporary approach. Intern Med J 2013,43(2),110-119","journal-title":"Intern Med J"},{"key":"ref=33","first-page":"349","author":"Frye R.F.","year":"2005","unstructured":"Frye R.F.; Capitano B.; Matzke G.R.;  Clinical Pharmacokinetics, 3\u00aaed 2005,349-364","journal-title":"Clinical Pharmacokinetics, 3\u00aaed"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077169","volume":"8","author":"Ye Z.K.","year":"2013","unstructured":"Ye Z.K.; Tang H.L.; Zhai S.D.; Benefits of therapeutic drug monitoring of vancomycin: A systematic review and meta-analysis. PLoS One 2013,8(10)","journal-title":"PLoS One"},{"key":"ref=35","year":"2018","unstructured":"2018"},{"key":"ref=36","unstructured":"Data from the EUCAST MIC distribution website,"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/1040841X.2017.1407745","volume":"44","author":"Florio W.","year":"2018","unstructured":"Florio W.; Morici P.; Ghelardi E.; Barnini S.; Lupetti A.; Recent advances in the microbiological diagnosis of bloodstream infections. Crit Rev Microbiol 2018,44(3),351-370","journal-title":"Crit Rev Microbiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2174\/1389201020666190319161511","volume":"20","author":"Bidu N.S.","year":"2019","unstructured":"Bidu N.S.; Fernandes B.J.D.; Dias E.J.C.; Filho J.N.C.; Bastos R.E.A.; Godoy A.L.P.C.; Azeredo F.J.; Pedreira J.N.R.; Couto R.D.; Vancomycin therapeutic regime adjustment in newborns and infants with bacterial infection: Case series. Curr Pharm Biotechnol 2019,20(4),346-351","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=39","first-page":"8","volume":"7","author":"Santos R.G.","year":"2016","unstructured":"Santos R.G.; Alves C.D.S.; Lemos L.B.; de Jesus I.S.; Lemos G da S.; Prescri\u00e7\u00f5es de antimicrobianos de uso restrito de pacientes internados em um hospital e ensino. Rev Bras Farm Hosp e Servi\u00e7os Sa\u00fade 2016,7(1),8-12","journal-title":"Rev Bras Farm Hosp e Servi\u00e7os Sa\u00fade"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-2122-x","volume":"17","author":"Mehl A.","year":"2017","unstructured":"Mehl A.; \u00c5svold B.O.; K\u00fcmmel A.; Lydersen S.; Paulsen J.; Haugan I.; Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: A prospective observational study. BMC Infect Dis 2017,17(1),1-11","journal-title":"BMC Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/jac\/dkn043","volume":"61","author":"Kelly S.","year":"2008","unstructured":"Kelly S.; Collins J.; Maguire M.; Gowing C.; Flanagan M.; Donnelly M.; Murphy P.G.; An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother 2008,61(4),901-907","journal-title":"J Antimicrob Chemother"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1590\/0074-0276140120","volume":"109","author":"Pinheiro L.","year":"2014","unstructured":"Pinheiro L.; Brito C.I.; Pereira V.C.; Oliveira A.; Camargo C.H.; Cunha M.L.; Reduced susceptibility to vancomycin and biofilm formation in methicillin-resistant Staphylococcus epidermidis isolated from blood cultures. Mem Inst Oswaldo Cruz 2014,109(7),871-878","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/jac\/dks490","volume":"68","author":"Dong Y.","year":"2013","unstructured":"Dong Y.; Chen S.; Wang Z.; Peng N.; Yu J.; Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm. J Antimicrob Chemother 2013,68(4),816-826","journal-title":"J Antimicrob Chemother"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1134\/S0026261717050125","volume":"86","author":"Kononova L.I.","year":"2017","unstructured":"Kononova L.I.; Filatova L.B.; Eroshenko D.V.; Korobov V.P.; Suppression of development of vancomycin-resistant Staphylococcus epidermidis by low-molecular-weight cationic peptides of the lantibiotic family. Microbiology 2017,86(5),571-582","journal-title":"Microbiology"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.bjid.2016.05.007","volume":"20","author":"Mart\u00ednez-Mel\u00e9ndez A.","year":"2016","unstructured":"Mart\u00ednez-Mel\u00e9ndez A.; Morf\u00edn-Otero R.; Villarreal-Trevi\u00f1o L.; Camacho-Ort\u00edz A.; Gonz\u00e1lez-Gonz\u00e1lez G.; Llaca-D\u00edaz J.; Rodr\u00edguez-Noriega E.; Garza-Gonz\u00e1lez E.; Molecular epidemiology of coagulase-negative bloodstream isolates: Detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23. Braz J Infect Dis 2016,20(5),419-428","journal-title":"Braz J Infect Dis"},{"key":"ref=46","year":"2019","unstructured":"Division of Infectious Disease Epidemiology (DIDE). Healthcare Associated Infections (HAI) Outbreak Investigation \/Notification Protocol. August, 2014, last accessed 27 March 2019"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.17058\/rjp.v4i3.4589","volume":"4","author":"Zanotto M.B.","year":"2014","unstructured":"Zanotto M.B.; Wappler P.R.; d\u2019Azevedo P.A.; Carneiro M.; Rauber J.M.; Valim A.R.M.; Avalia\u00e7\u00e3o dos n\u00edveis s\u00e9ricos de vancomicina em pacientes internados em um hospital de ensino da regi\u00e3o central do Rio Grande do Sul - Brasil. Rev Jovens Pesqui 2014,4(3),38-51","journal-title":"Rev Jovens Pesqui"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01845-16","volume":"61","author":"Song K.H.","year":"2017","unstructured":"Song K.H.; Kim M.; Kim C.J.; Cho J.E.; Choi Y.J.; Park J.S.; Ahn S.; Jang H.C.; Park K.H.; Jung S.I.; Yoon N.; Kim D.M.; Hwang J.H.; Lee C.S.; Lee J.H.; Kwak Y.G.; Kim E.S.; Park S.Y.; Park Y.; Lee K.S.; Lee Y.S.; Kim H.B.; Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections. Antimicrob Agents Chemother 2017,61(3),1-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1099\/mic.0.000178","volume":"161","author":"Czekaj T.","year":"2015","unstructured":"Czekaj T.; Ciszewski M.; Szewczyk E.M.; Staphylococcus haemolyticus - an emerging threat in the twilight of the antibiotics age. Microbiology 2015,161(11),2061-2068","journal-title":"Microbiology"},{"key":"ref=50","first-page":"1","volume":"1","author":"Viau R.","year":"2015","unstructured":"Viau R.; Hujer A.M.; Hujer K.M.; Bonomo R.A.; Jump R.L.P.; infectious diseases, a report on diseases caused by bacteria, viruses, fungi and parasites. Br Rep 2015,1,1-4","journal-title":"Br Rep"},{"key":"ref=51","first-page":"1","volume":"17","author":"Alves G.C.","year":"2019","unstructured":"Alves G.C.; da S. Chequer, F.M.D.; Sanches, C. Concentra\u00e7\u00f5es efetivas de vancomicina em crian\u00e7as: Estudo transversal. Einstein (Sao Paulo) 2019,17(1),1-7","journal-title":"Einstein (Sao Paulo)"},{"key":"ref=52","first-page":"199","volume":"34","author":"Alves M.L.P.","year":"2012","unstructured":"Alves M.L.P.; Melo G.A.N.; Yamada S.S.; Nishiyama P.; Therapeutic monitoring of vancomycin. Acta Sci Heal Sci 2012,34(2),199-204","journal-title":"Acta Sci Heal Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s10156-012-0458-8","volume":"19","author":"Ito H.","year":"2013","unstructured":"Ito H.; Shime N.; Kosaka T.; Pharmacokinetics of glycopeptide antibiotics in children. J Infect Chemother 2013,19(2),352-355","journal-title":"J Infect Chemother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","volume":"42","author":"Rybak M.J.","year":"2006","unstructured":"Rybak M.J.; The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006,42(Suppl. 1),S35","journal-title":"Clin Infect Dis"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/180538\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/180538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T05:08:42Z","timestamp":1613797722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180538\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,9,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201021666200327162402","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}